A new Kazakh-made vaccine QazCoVac-P is now being tested on humans. The developers of the vaccine announced the transition to the second stage of trials. The Research Institute for Biological Safety Problems explained that 200 volunteers will take part in the trials. The immunogenicity and safety of QazCoVac-P will be studied at this stage. The developers noted that this vaccine will be taken more easily.
Also, the experts of the research institute reported that two more vector vaccines are under development. According to them, the production of a modified version of QazVac based on the delta strain is already nearing the finish line.
Translation by Saniya Sakenova
Editing by Galiya Khassenkhanova
